Teva Pharmaceutical Industries (TEVJF) Convertible Debt (2009 - 2010)

Teva Pharmaceutical Industries (TEVJF) recorded quarterly Convertible Debt of $13.0 million in Q4 2010, down 98.41% on a QoQ basis from $817.0 million in Q4 2009, and down 98.41% year-over-year from $817.0 million in Q4 2009.

Teva Pharmaceutical Industries (TEVJF) Convertible Debt (2009 - 2010) Analysis & Trends

Teva Pharmaceutical Industries has disclosed Convertible Debt across 2 years of filings, most recently posting $13.0 million for Q4 2010.

  • Quarterly Convertible Debt fell 98.41% year-over-year to $13.0 million in Q4 2010, while the trailing twelve-month figure through Dec 2010 was $13.0 million (down 98.41% YoY) and the FY2010 annual result came in at $13.0 million, down 98.41% from the prior year.
  • Convertible Debt slipped to $13.0 million in Q4 2010, from $817.0 million in the prior quarter.
  • Over five years, Convertible Debt peaked at $817.0 million in Q4 2009 and troughed at $13.0 million in Q4 2010.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Teva Pharmaceutical Industries - - 1.97 Bn

Historic Data

Download Data
DateValue
Dec 31, 2010 13.00 Mn
Dec 31, 2009 817.00 Mn